Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Project Name | Project Stage | Molecule Type | Host Species | Therapeutic Area | Indications |
| ALPP/ALPPL2 mAb - 01 | PCC | Solid Tumor | Endometrial cancer,Ovarian cancer | ||
| BCMA VHH - 01 | Lead | Hematological Malignancy | Multiple myeloma | ||
| CCR8 mAb - 01 | PCC | Solid Tumor | Solid tumor | ||
| CCR8 mAb - 02 | Lead | Solid Tumor | Solid tumor | ||
| CCR8 mAb - 03 | PCC | Solid Tumor | Solid tumor | ||
| CD25 mAb - 01 | PCC | Solid Tumor | Solid tumor | ||
| CDH17 mAb - 01 | PCC | Solid Tumor | Colorectal cancer,Gastric Cancer | ||
| CXCR4 mAb - 01 | Lead | Hematological Malignancy,AutoImmunity | Blood tumor,Solid tumor |
| Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
| NGF mAb | Monospecific antibody | Neurological disease | Cancer pain | Phase II | Global (except China) |
| 5-HT1F agonist | Small molecule | Neurological disease | Migraine | Phase I | Global |
| TNFα and TGF-β1 inhibitor | Small molecule | Respiratory disease | IPF | Phase II | Global (except China) |
| Capsid Assembly Inhibitors for HBV | Small molecule | Infectious and parasitic diseases | HBV | Phase III | Global (except China) |
| PI3Kδ inhibitor | Small molecule | Oncology/Cancer | Hematologic malignancies | Phase I | Global |
| Capsid Assembly Inhibitors for HBV | Small molecule | Infectious and parasitic diseases | HBV | Phase I | Global (except China) |
| RET high selective inhibitor | Small molecule | Oncology/Cancer | NSCLC,Medullary thyroid cancer,Thyroid cancer | Phase I | Global |
| A SSRI & Partial 5-HT1A Agonist | Small molecule | Neurological disease | Depression | Phase III | Global |
| sGC stimulator | Small molecule | Cardiovascular | PAH,CTEPH,HFrEF,CKD | Phase I | Global |
| SGLT2 inhibitor | Small molecule | Metabolic disease | Diabetes | Phase III | Global (except China) |
| FXR Agonist | Small molecule | Metabolic disease | Diabetic kidney disease | Phase I | Global |
| ACC inhibitor treating NASH | Small molecule | Metabolic disease | NASH | IND | Global |
| Oxazolidone (new compounds) antibiotics | Small molecule | Infectious and parasitic diseases | gram-positive bacterial infections | IND | Global |
| HIF-PHs inhibitor for CKD and Renal anemia | Small molecule | Blood and Clotting disease | CKD,Renal anemia | Phase I | Global (except China) |
| PI3K/mTOR dual inhibitor | Small molecule | Oncology/Cancer,Respiratory disease | IPF,solid tumor | Phase I | Global (except China) |
| Modified vilazodone | Small molecule | Neurological disease | Major Depressive Disorder | BE | Global |
| CLDN 18.2 CAR-T | Cell therapy | Oncology/Cancer | Gastric Cancer,Pancreatic Cancer | IND | Global |
| EpCAM CAR-T | Cell therapy | Oncology/Cancer | Colorectal Cancer,Gastric Cancer,Other Cancer | IIT | Global |
| PI3Kδ inhibitor | Small molecule | Oncology/Cancer | Advanced solid tumors | Phase I | Global |
| PARP inhibitor | Small molecule | Oncology/Cancer | Advanced malignant solid tumors | Phase I | Global |
| Liver-Targeting THR-β Agonist | Small molecule | Metabolic disease | Nonalcoholic Steatohepatitis (NASH) | Phase I | Global |
| PI3Kδ inhibitor | Small molecule | Oncology/Cancer | Solid tumor,Hematological malignancies | PCC | Global |
| Best-in-class IRAK4 Degrader | Immunological disease | Psoriasis/RA/Inflammatory bowel disease (IBD)/autoimmune inflammatory diseases | PCC | Global | |
| Best-in-class BCL-XL PROTAC | Ophthalmology disease | diabetic macular edema/diabetic retinopathy | Preclinical | Global | |
| Novel Target Small Molecule Inhibitor for Heart Failure | Cardiovascular | Chronic heart failure | IND | Global | |
| GPCR selective agonist | Immunological disease | Duchenne muscular dystrophy/Systemic lupus erythematous;/Ulcerative colitis;/Ankylosing spondylitis | PCC | Global | |
| PD-1/IL-2Rβγ biased bifunction fusion protein | Oncology/Cancer | Gastric cancer/Pancreatic cancer/Lung cancer/Colorectal cancer | Phase I | Global | |
| EGFR/cMet ADC | Oncology/Cancer | Gastric cancer/Pancreatic cancer/Colorectal cancer/ Lung cancer | IND | Global | |
| High gastrointestinal distribution TRPA1 inhibitor | Immunological disease | Inflammatory bowel disease | IND Approved | Global | |
| acro_bio_test_1.0.1 | Oncology - Colorectal/Diseases of the blood and blood-forming organs | The asset treatment results in decrease of pCREB, a downstream PD marker of adenosine signaling./The asset treatment results in decrease of pCREB, a downstream PD marker of adenosine signaling. | Preclinical | Global (except China) |
2% serum diluted by Dilution Buffer : Biotinylated SARS-CoV-2 S protein RBD was put into, the background value is 2.383 and 2.148; 2% serum diluted by DB-02 : Biotinylated SARS-CoV-2 S protein RBD was put into, the background value is 0.262 and 0.263. In the existence of DB-02, the serum background values significantly decreased. Note: Dilution Buffer is Wash Buffer with 0.5% (w/v) bovine serum albumin (BSA), 50 mL.
Inhibition of Europium-chelate labeled human TL1A: FA labeled human DR3 binding by Human Anti-TL1A Neutralizing Antibody
Premix serial dilutions of Human Anti-TL1A Neutralizing Antibody (1:2 serial dilution, from 10 μg/mL to 0.01953125 μg/mL (66.6667-0.1302 nM)) and Human TL1A Protein Europi-um-chelate and incubate at room temperature (20℃-25℃) for 0.5 hours. Then add FA La-beled Human DR3 Protein and incubate at room temperature (20℃-25℃) for 0.5 hours. Detection was performed with IC50 of 2.816nM. The assay was performed according to the above-described Datasheet (QC tested).
This web search service is supported by Google Inc.
A-Z
